grant
Investigation of skin cancer and skin disease
Organization NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY2025Adverse ExperienceAdverse eventAnti-Cancer AgentsAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsArmed Forces PersonnelBiologyCancer CenterCancer DrugCancer TreatmentCancersChimera ProteinChimeric ProteinsClinicalClinical ManagementCollaborationsComplexCutaneousCutaneous DisorderDermatologicDermatologicalDermatosesDiagnosisDysfunctionFunctional disorderFungus DiseasesFusion ProteinHSC transplantationHealthHealth SciencesHematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationImmunooncologyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectInflammationInflammatoryInvestigationInvestigatorsKeratinocyte carcinomaLearningMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Skin NeoplasmMalignant TumorMedical centerMilitaryMilitary PersonnelMitesMycosesNational Institutes of HealthNeoplastic Disease Chemotherapeutic AgentsNon-Melanoma Skin CancerOrganPathologyPatient CarePatient Care DeliveryPatientsPhysiopathologyPrognostic MarkerResearch PersonnelResearchersRiskRunningSebaceous AdenocarcinomaSebaceous CarcinomaSebaceous Gland AdenocarcinomaSkinSkin CancerSkin CarcinomaSkin DiseasesSkin Diseases and ManifestationsSkin NeoplasmsSkin TumorTreatment ProtocolsTreatment RegimenTreatment ScheduleTumor-Specific Treatment AgentsUnited States National Institutes of HealthUniversity Health Servicesanti-cancer druganti-cancer immunotherapyanti-cancer therapyanticancer immunotherapybiomarker of triple-negative melanomablood stem cell transplantationcancer immunotherapycancer therapycancer-directed therapycare for patientscare of patientscaring for patientsclinical centercutaneous diseasedermal diseasedermal disorderdiagnostic biomarkerdiagnostic markerfungal infectionfungus infectionhematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitor cell transplantationhypoimmunityimmune deficiencyimmune suppressionimmune suppressive activityimmune suppressive functionimmune-based cancer therapiesimmune-mediated adverse eventsimmune-oncologyimmune-related adverse effectimmune-related adverse eventsimmune-related adverse reactionimmuno oncologyimmunodeficiencyimmunology oncologyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunotherapy for cancerimmunotherapy of cancerinterestmalignancymalignant skin tumormelanoma associated biomarkermelanoma biomarkersmilitary populationneoplasm/cancernew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynonmelanoma skin cancernovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachoncoimmunologyoncology programpathophysiologypredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreventpreventingprognostic biomarkerprognostic indicatorproteogenomicsskin disorder
Description preview
We have been investigating skin diseases in patients using multiple approaches. This includes studying skin cancers, inflammatory dermatoses, skin diseases arising in patients with immunosuppression, and skin adverse events related to cancer treatments. Specifically, we are investigating skin tumors that arise in patients taking a novel cancer…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click